Target Inhibition (WP7, WP8, WP9, WP10)
Develops two alternative, yet complementary, strategies aimed to attack the problem of P. aeruginosa
- novel drugs from the screening of chemical libraries against specifically selected targets and the characterisation of the mode of action of novel drugs with antibacterial activity discovered by some members of the partnership.
- novel antisense inhibitors of bacterial targets by peptide nucleic acids (PNA) delivery.
The combined efforts are expected to result in a panel of new agents for the treatment of P. aeruginosa
infections in patients with CF and other patient risk groups and a robust network of technologies that could also be applied for the development of anti-microbial drugs for other bacterial pathogens, especially other Gram-negative bacteria, such as B. cenocepacia